Novogen Gains New US Health Supplement Patent And Receives Milestone Payment
December 03 2003 - 9:55AM
PR Newswire (US)
Novogen Gains New US Health Supplement Patent And Receives
Milestone Payment STAMFORD, Conn., Dec. 3 /PRNewswire-FirstCall/ --
Novogen Limited has been granted the U.S. patent covering health
supplements based on the use of soy isoflavones in tablet or
capsule form. This patent has been licensed worldwide, with the
exception of Australia and New Zealand, to Solae LLC of St Louis,
Mo. Solae is a joint venture of the DuPont Company and Bunge. The
issuance of the patent is a valuable addition to the patent
portfolio of Novogen in the area of isoflavones and health
supplements as well as an important licensing milestone between the
Company and Solae. Based upon this newly issued patent, Solae has
initiated a new patent infringement suit in the U.S. against both
Archer Daniels Midland Company and Amerfit Inc. Novogen is also
listed in Australia (ASX:NRT). The company manages its
international research and development program using the expertise
and clinical research capabilities of universities and hospitals in
the U.S., Australia and other key international locations.
Statements herein that are not descriptions of historical facts are
forward-looking and subject to risk and uncertainties. Actual
results could differ materially from those currently anticipated
due to a number of factors, including those set forth in the
Company's Securities and Exchange Commission filings under "Risk
Factors," including risks relating to the early stage of products
under development; uncertainties relating to clinical trials;
dependence on third parties; future capital needs; and risks
relating to the commercialization, if any, of the Company's
proposed products (such as marketing, safety, regulatory, patent,
product liability, supply, competition and other risks). CONTACT:
Warren Lancaster of Novogen, +1-203-327-1188, or David Sheon,
+1-202-518-6321, for Novogen. DATASOURCE: Novogen Limited CONTACT:
Warren Lancaster of Novogen, +1-203-327-1188, or David Sheon,
+1-202-518-6321, for Novogen
Copyright
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jul 2023 to Jul 2024